Epigenetic Mechanisms in Autoimmune Thyroid Diseases: Bridging Research and Clinical Applications.

Autoimmune thyroid disease (AITD) exemplifies an organ-specific autoimmune disorder, including Hashimoto's thyroiditis (HT) and Graves' disease (GD). HT is characterized by hypothyroidism, whereas GD primarily presents as hyperthyroidism. Immunological evidence indicates that AITD pathogenesis requires both a permissive genetic background and environmental triggers to initiate and sustain disease progression. However, the exact molecular and cellular pathways through which these elements synergize to trigger and sustain autoimmune responses remain unclear. Emerging evidence suggests that epigenetic regulation serves as the key interface decoding genetic predisposition through environmental stimuli in AITD etiology. Studies show that environmental epigenetic reprogramming initiates AITD development in genetically susceptible individuals. Epigenetic regulators, including DNA methylation, histone modifications, and non-coding RNA activity, finely tune transcriptional outputs to influence disease trajectories. Beyond elucidating AITD pathogenesis, these epigenetic alterations offer clinical value as diagnostic biomarkers and modifiable therapeutic targets, facilitating precision medicine approaches from early detection to customized interventions. These epigenetic modifications not only elucidate AITD pathophysiology but also provide measurable markers for early diagnosis and molecular targets for personalized treatment strategies.